Denise Sighel

Dr. Denise Sighel

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
MMMariachiara Micaelli
Mariachiara Micaelli
AVAndrea Dalle Vedove
Andrea Dalle Vedove
LCLinda Cerofolini
Linda Cerofolini
JVjacopo vigna
jacopo vigna
DSDenise Sighel
Denise Sighel
APAlessandro Provenzani
Alessandro Provenzani
YTHDF proteins bind the N 6-methyladenosine (m6A)-modified mRNAs, influencing their processing, stability, and translation. Therefore, the members of this protein family play crucial roles in gene regulation and several physiological and pathophysiological conditions. YTHDF proteins contain a hydrophobic pocket that accommodates the m6A embedded in the RRACH consensus sequence on mRNAs. We exploited the presence of this cage to set up an m6A-competitive assay and performed a high-throughput screen aimed at identifying ligands binding in the m6A pocket. We report the organoselenium compound ebselen as the first-in-class inhibitor of the YTHDF m6A-binding domain. Ebselen, whose interaction with YTHDF proteins was validated via orthogonal assays, cannot discriminate between the binding domains of the three YTHDF paralogs but can disrupt the interaction of the YTHDF m6A domain with the m6A-decorated mRNA targets. X-ray, mass spectrometry, and NMR studies indicate that in YTHDF1 ebselen binds close to the m6A cage, covalently to the Cys412 cysteine, or interacts reversibly depending on the reducing environment. We also showed that ebselen engages YTHDF proteins within cells, interfering with their mRNA binding. Finally, we produced a series of ebselen structural analogs that can interact with the YTHDF m6A domain, proving that ebselen expansion is amenable for developing new inhibitors. Our work demonstrates the feasibility of drugging the YTH domain in YTHDF proteins and opens new avenues for the development of disruptors of m6A recognition.

1 April 2021 in Cell Reports
Verified
Journal Article
Open access
DSDenise Sighel
Denise Sighel
MNMichela Notarangelo
Michela Notarangelo
SAShintaro Aibara
Shintaro Aibara
ARAngela Re
Angela Re
GRGianluca Ricci
Gianluca Ricci
AQAlessandro Quattrone
Alessandro Quattrone
Glioblastoma stem cells (GSCs) resist current glioblastoma (GBM) therapies. GSCs rely highly on oxidative phosphorylation (OXPHOS), whose function requires mitochondrial translation. Here we explore the therapeutic potential of targeting mitochondrial translation and report the results of high-content screening with putative blockers of mitochondrial ribosomes. We identify the bacterial antibiotic quinupristin/dalfopristin (Q/D) as an effective suppressor of GSC growth. Q/D also decreases the clonogenicity of GSCs in vitro, consequently dysregulating the cell cycle and inducing apoptosis. Cryoelectron microscopy (cryo-EM) reveals that Q/D binds to the large mitoribosomal subunit, inhibiting mitochondrial protein synthesis and functionally dysregulating OXPHOS complexes. These data suggest that targeting mitochondrial translation could be explored to therapeutically suppress GSC growth in GBM and that Q/D could potentially be repurposed for cancer treatment.

3 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Ines ManciniInes Mancini
Ines Mancini
JVjacopo vigna
jacopo vigna
DSDenise Sighel
Denise Sighel
ADAndrea Defant
Andrea Defant
In recent decades, molecular hybridization has proven to be an efficient tool for obtaining new synthetic molecules to treat different diseases. Based on the core idea of covalently combining at least two pharmacophore fragments present in different drugs and/or bioactive molecules, the new hybrids have shown advantages when compared with the compounds of origin. Hybridization could be successfully applied to anticancer drug discovery, where efforts are underway to develop novel therapeutics which are safer and more effective than those currently in use. Molecules presenting naphthoquinone moieties are involved in redox processes and in other molecular mechanisms affecting cancer cells. Naphthoquinones have been shown to inhibit cancer cell growth and are considered privileged structures and useful templates in the design of hybrids. The present work aims at summarizing the current knowledge on antitumor hybrids built using 1,4- and 1,2-naphthoquinone (present in natural compounds as lawsone, napabucasin, plumbagin, lapachol, α-lapachone, and β -lapachone), and the related quinolone- and isoquinolinedione scaffolds reported in the literature up to 2021. In detail, the design and synthetic approaches adopted to produce the reported compounds are highlighted, the structural fragments considered in hybridization and their biological activities are described, and the structure–activity relationships and the computational analyses applied are underlined.

10 August 2018 in Molecules
Verified
Journal Article
Open access
PDF file
BBBartolomeo Bosco
Bartolomeo Bosco
ADAndrea Defant
Andrea Defant
AMAndrea Messina
Andrea Messina
TITania Incitti
Tania Incitti
DSDenise Sighel
Denise Sighel
Ines ManciniInes Mancini
Ines Mancini
Reversine is a potent antitumor 2,6-diamino-substituted purine acting as an Aurora kinases inhibitor and interfering with cancer cell cycle progression. In this study we describe three reversine-related molecules, designed by docking calculation, that present structural modifications in the diamino units at positions 2 and 6. We investigated the conformations of the most stable prototropic tautomers of one of these molecules, the N6-cyclohexyl-N6-methyl-N2-phenyl-7H-purine-2,6-diamine (3), by Density Functional Theory (DFT) calculation in the gas phase, water and chloroform, the last solvent considered to give insights into the detection of broad signals in NMR analysis. In all cases the HN(9) tautomer resulted more stable than the HN(7) form, but the most stable conformations changed in different solvents. Molecules 1–3 were evaluated on MCF-7 breast and HCT116 colorectal cancer cell lines showing that, while being less cytotoxic than reversine, they still caused cell cycle arrest in G2/M phase and polyploidy. Unlike reversine, which produced a pronounced cell cycle arrest in G2/M phase in all the cell lines used, similar concentrations of 1–3 were effective only in cells where p53 was deleted or down-regulated. Therefore, our findings support a potential selective role of these structurally simplified, reversine-related molecules in p53-defective cancer cells.

26 January 2019 in Fermentation
Verified
Journal Article
Open access
PDF file
NLNassima Leulmi
Nassima Leulmi
DSDenise Sighel
Denise Sighel
ADAndrea Defant
Andrea Defant
KKKarima Khenaka
Karima Khenaka
ABAbderrahmane Boulahrouf
Abderrahmane Boulahrouf
Ines ManciniInes Mancini
Ines Mancini
Nigericin, one of the main ionophoric polyethers produced by various Streptomyces strains, presents relevant biological activities including antibacterial and recently studied antitumor properties. This work describes the influence of different culture conditions on the production of this metabolite by Streptomyces sp. SF10, isolated from a semi-arid soil sample collected at Chélia Mountain, in Khenchela (Northeastern Algeria) and identified as Streptomyces youssoufiensis. The extracts from the strain, cultured in a solid state or submerged fermentation conditions, using several carbon sources at different pH values, in the presence or absence of iron (II) sulfate and in co-culture with other Streptomyces species, were analyzed using a high-performance liquid chromatography (HPLC) system equipped with an evaporative light scattering detector (ELSD). The best culture conditions provided a concentration of nigericin of 0.490 ± 0.001 mg/mL in the extract. The HPLC-ELSD method, optimized here for the quantitative detection of nigericin, can find wider applications in the analysis of several other metabolites characterized by a similar polycyclic polyether structure or, more generally, by the lack of significant chromophores in their molecular structure.

30 November 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DSDenise Sighel
Denise Sighel
GBGiulia Battistini
Giulia Battistini
EREmanuele Filiberto Rosatti
Emanuele Filiberto Rosatti
JVJacopo Vigna
Jacopo Vigna
MPMatteo Pavan
Matteo Pavan
Ines ManciniInes Mancini
Ines Mancini